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1. Introduction
Human immunodeficiency virus-1 (HIV-1) engulfs 33 millions of life as per the latest UN
AIDS  report  [Saxena,  Tiwari.,  et  al.,  2012]  and  the  effect  worsens  up  when  it  causes
dementia  with  alarming  occurrence  worldwide  but  the  mechanism  through  which  it
happens is still not well understood, and is in the embryonic stages. The estimated overall
prevalence of nervous system disorders among patients receiving highly active antiretrovi‐
ral  therapy but also requiring neurological care is over 25% (Singh et  al.,  2011).  Accord‐
ing to WHO there are ~ 34 million people in the world infected with HIV. Out of that 95
percent  of  these  cases  as  well  as  deaths  from  AIDS  occur  in  the  developing  world.
Dementia (HIV-associated dementia) is becoming common in HIV infected adults having
prevalence up to 40% in western countries  where clade B prevails  (Sacktor et  al.,  2007).
Dementia cannot be considered as a disease by itself but it is the term used to describe a
set of symptoms resulting from damages and disorders affecting the brain. These symp‐
toms can be caused by a multitude of diseases and depend upon the specific brain regions
affected. These symptoms appear as a variety of cognitive, behavioural,  affective, motor,
and  psychiatric  disorders.  Dementia  can  be  caused  by  a  variety  of  diseases,  known  as
neurodegenerative diseases resulting from protein aggregation in the brain. Many studies
related to this area are been carried out in respect to this, to provide new insights (Saxena
et al., 2012). HIV-1 infects macrophages and microglia, and there is an indirect pathway to
neuronal  injury which happens due to release of  macrophage,  microglial  and astrocytes
toxins and viral proteins. The toxins which are released over stimulate neurons, form free
radicals, finally leading to neurodegenerative diseases. The cognitive and motor dysfunc‐
tion which is observed in HIV patients is termed as HIV associated dementia (HAD). The
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prevalence of the dementia is  eventually increasing as AIDS patients are now surviving
more.  HIV-1 replicates  in monocyte and macrophage but  not  as  severe as  in infected T
cells  and blood mononuclear cells  (Sundaravaradan et  al.,  2006).  These cells  differentiate
and travel to several organs, henceforth acting as a source of infectious virus and secret‐
ed viral proteins to cause pathological issues and alternating several signalling pathways
and distorting many cellular transcription factors, ultimately resulting in HIV-1 pathogen‐
esis.  Increased  transcription  leads  to  the  upregulation  of  virus  production,  and  hence
increased  production  of  viral  proteins  (gp120,  Tat,  Nef,  and  Vpr)  (Gandhi  et  al.,  2020;
Samikkannu et al.,  2010; Saiyed et al.,  2011; Saxena et al.,  2012; Saxena et al.,  2012).  The
high  concentration  of  these  toxic  proteins  lead  to  distorted  cellular  functions,  and  in‐
creased production of toxic metabolites, finally leading to organ-specific like neuroAIDS,
in case  of  viral  entry inside the brain (Kilareski  et  al.,  2009).  Antiretroviral  therapy has
increased  the  lifespan  of  HIV  patients,  but  CNS  function  often  remains  diminished
sometimes developing into HIV-associated dementia and the severity and progression of
dementia is studied to be increased with the effect of drug abuse [Reddy et al., 2012; Ferris
et al., 2008].
2. Prevalence
The prevalence of HAD is estimated to be more than 30% of HIV infected patients, and it is
still reported to be increasing (Dean et al., 2012). Improvements in control of peripheral viral
replication and the treatment of opportunistic infections, helps in extending life expectancy,
resulting in an increase in neuropathogenesis. We are seeing a linear increase in prevalence in
rich countries, but an exponential increase in low-income countries. Just under half of people
with dementia live in high-income countries, 39% live in middle-income countries, and only
14% live in low-income countries. Increasing living standards, in low income countries such
as India (Shankar et al., 2005), may lead to increased life expectancy, which may increase the
frequency of dementia cases. As biggest risk factor for dementia is age, a longer-living global
population means there will be more people with dementia. The report predicts that the
numbers of people with dementia will double every 20 years, to 65.7 million in 2030 and 115.4
million in 2050. Most of this increase will be in developing countries (Prince et al., 2012). A
more complete understanding of the pathogenesis of HAD will help in identifying therapeutic
targets for its prevention and treatment. The global age standardized death rate for dementia
is ~ 6.7 per 100,000 for males and 7.7 per 100,000 for females. According to the World Health
Organization, dementia mortality rate for India is 13.5 per 100,000 males and 11.1 for 100,000
females, which is quite alarming (Prince et al., 2012).
3. HIV- Mechanism of neuronal injury
Presently, neuropathogenesis is winning, because there is an incomplete knowledge about the
mechanism of HIV infection causing neuronal injury and apoptosis in the host (Fig. 1). HIV
Current Perspectives in HIV Infection110
enters the central nervous system through infected monocytes and leads to pathogenesis
involving activation of macrophages and microglia and further toxin release, that activates
several pathways leading to neuronal dysfunction. There are several extracellular and
intracellular signalling pathways, which when activated lead to macrophage or microglial
activation, and induction in neurons and astrocytes. These pathways are of potential thera‐
peutic importance as targets for the prevention or treatment of neuropathogenesis.
Figure 1. HIV virus can enter the CNS by altering the integrity of blood brain barrier.
4. Neuropathology of AIDS
HIV-1 is capable of causing a multi-system disorder including the CNS. HIV-1 enters the CNS
at the early phase of infection, it persists and induces several motor and cognitive disorders
leading to behavioural changes. Major clinical symptoms include impaired short term-
memory, reduced mental concentration, weakness, slowness of hand and leg movement and
depression accompanied by behavioural issues like personality disorders, lethargy and social
withdrawal. These neurological and psychiatric symptoms caused by HIV-1 infection,
constitute together as neuropathogenesis. A more subtle form of CNS dysfunction, known as
minor cognitive motor disorder (MCMD), is also seen common in HIV patients. HAD cannot
be controlled by HAART, HIV-1 infection becomes chronic and even rise in disease has been
reported. The HIV-1 associated neuropathology is characterized by the infiltration of macro‐
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phages into the CNS, the formation of microglial nodules and multinucleated giant cells,
astrocyte activation and damage; neuronal loss in ganglions and hippocampus, myelin
damage, axonal damage and presence of HIV-1 in the CSF. MRI reports say that HIV infection
is associated with progressive cortical atrophy which might be caused by neuronal loss and
demyelination worsening in certain cognitive functions (Ghafouri et al., 2006).
5. HIV entry into the brain and initiation of HAD
HIV-1 infects cells having major HIV-1 receptors,  CD4 and CD8, and several chemokine
receptors which are known to be as HIV-1 co-receptors which help in the attachment of
the virus to the cell and membrane fusion leading to viral entry. Infected CD4+ T cells and
monocytes circulating in the blood are the potential source of CNS infection. HIV-1 infected
cells can be either highly active producers or low/non producers of viruses. Both types of
infections  occur  in  the  CNS.  Studies  of  different  astrocytes  cell  lines,  demonstrated  the
presence of large quantities of Rev in the cytoplasm. Changes in cell environment, like the
elevation  in  the  level  of  cytokines  such  as  TNF-α  and  IL-1β,  might  reactivate  virus
production (Ghafouri et al., 2006). During early infection, HIV enters the CNS (Bertin et al.,
2012) and attacks cells macrophages and microglial cells (Foley et al., 2008). But along with
this infection, periphery factors (non-CNS) are also important for initiating neurodegener‐
ation and triggering dementia, which are like for example; increased number of circulat‐
ing monocytes that express CD16 and CD69. The cells which get activated by viral entry,
progressively  adhere  to  the  endothelium  membrane  of  the  brain  microvasculature,  and
further  transmigrate,  triggering  a  spontaneous  array  of  harmful  processes  which  might
finally lead to the loss of Blood Brain Barrier (BBB) integrity making it easy for virus to
enter and replicate inside the brain. The BBB is crucial in HIV infection of the CNS. BBB
is composed of specialized Human brain microvascular endothelial cells (HBMECs), which
do not have any opening and are connected by intercellular junctions in an impermeable
single  layer.  BBB  plays  a  central  role  in  neuropathogenesis  as  it  serves  as  the  channel
through which  free  virus  and infected  immune cells  enter  the  brain.  The  BBB loses  its
integrity  and  permeability  due  to  progressive  HIV  infection  and  immune  compromisa‐
tion, which leads to easy entry of toxins, free virus, infected and activated monocytes into
the brain. It has been reported that HIV-1 gp120 protein and also Tat protein are behind
BBB  disregulation.  PKC  signaling  pathways  and  receptor-mediated  Ca2+  release  are  the
involved pathways resulting into cytotoxicity of the brain endothelial cells (Kanmogne et
al.,  2005)  leading  to  downregulation  and  rupture  of  tight  junction  proteins  (TJPs)  of
HBMECs, by the induction of proteasome by HIV-1. It  has been studied that circulating
virus or envelope proteins may also cause BBB dysfunction during primary infection. CNS
infection of HIV is detected by viral RNA load in CSF (Woods et al., 2009; Morgan et al.,
2011).  Chemokines  like  monocyte  chemoattractant  protein  (MCP)-1  control  PBMCs
relocation through BBB.  Cellular  migration engages  adhesion molecules  and differential
regulation of  inflammatory cytokines,  leading to BBB disintegration and finally immune
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dysregulation by letting sufficient entry of infected or activated immune cells into the brain
causing neuronal injury.
6. Types of CNS cells invaded by HIV-1
BBB is selectively permeable, made up of firmly concurrent brain microvascular endothelial
cells, and its major role is to separate the CNS from the periphery. It manages the trafficking
of cells and molecules across it into the brain parenchyma. For the purpose of brain entry,
HIV-1 has to cross the BBB using several mechanisms which are still poorly understood and
are unclear. Numerous in vitro experimentations have been done to understand the mecha‐
nisms of HIV-1 introduction into the CNS via BBB. It is reported that the severity of HIV-1
associated neuropathogenesis is dependent on amount of HIV DNA circulating in PBMCs
(Shiramizu et al., 2009). It is hypothesized that HIV-1 enters the CNS, in disguise as a commuter
in cells trafficking till the brain (Verma et al., 2010). CD4+ cells, like T cells and monocytes are
infected by HIV-1, which circulate in blood and have the ability to cross the BBB and introduce
the infection into CNS. Though presence of CD4 receptors in human brain microvascular
endothelial cells is still a matter of debate whereas its presence is studied along with expression
of HIV-1 co-receptors have also being reported on primary human brain's microvascular
endothelial cells. Other proposed hypothesis for the entry of HIV-1 is the migration between/
transcytosis of endothelial cells. All types of the CNS cells like astrocytes (Wang et al., 2009),
oligodendrocytes, neurons, macrophage and microglia, are easily infected by HIV-1 as they
have receptors and co-receptors for HIV-1 entry, but only macrophage and microglia get
infected most commonly which are the resident immunocompetent cells of the brain (Gen‐
dleman et al., 1985). Expression of CCL2/MCP-1 in astrocytes is enhanced by nef via calmodulin
dependent pathway. Consequently, increased CCL2/MCP-1 functions as a chemoattractant for
monocytes, thereby facilitating entry of monocytes into the brain (Lehmann et al., 2006).
Peripheral macrophage population is necessary to be refilled, which is compensated by the
migration of monocytes into the CNS, resulting in major drawback of facilitating the entry of
intracellular virus. Microglia and monocyte-derived macrophages are the main culprits of
HIV-1 CNS infection. Immunostaining experiments have shown HIV-1 infection in parenchy‐
mal microglia, but it is still unclear that whether the HIV-1 immunopositive microglia receives
influx of infected cells from blood or directly results from prolonged infection in the CNS. In-
vitro experiments demonstrate that HIV-1 replication takes place in primary microglia isolated
from adults and infants leading to cytopathology. Microglial cells are the major targets as they
express CD4/CCR5 major receptors/co-receptors which is a necessity for HIV-1 infection. On
the other hand astrocytes express CXCR4 and other HIV-1 coreceptors like CCR5, but do not
express CD4 receptors and are still reported to be infected by HIV-1 mechanisms to which are
still unclear. Also in vivo, oligodendrocytes infection by HIV-1 remains unclear and less
understood as they do not have CD4 receptors. Mostly there is absence of in vivo infection in
neurons, however sometimes presence of HIV-1 DNA and proteins in neurons have been
reported too, leading to need of further studies. Various pathways for the entry of virus into
the brain have been studied like (i) direct entry, (ii) transcytosis, (iii) Trojan horse hypothesis
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for entry, which states that HIV enters the CNS via infected CD4 + AND T-cells which are
capable of crossing BBB and they reach CNS and are also capable of transferring infection to
other CNS cells too (Fig. 2).
Figure 2. HIV-1 neuroinvasion. 1) "Trojan Horse hypothesis" for entry of HIV-1 into the brain via migration of infected
monocytes which differentiate into perivascular macrophage. 2) The passage of infected CD4+ T cells into the brain.
Other probable causes of CNS infection might be: 3) the direct entrance of the virus via tight junctions across the
membrane and 4) entrance of HIV-1 by transcytosis phenomenon.
7. Crosstalk between the peripheral and CNS immunity
The way by which HIV-1-infected monocytes escape immune surveillance can be explained
by “Trojan horse cell” model. The “support” needed for the viral entry is through CNS-
produced chemokines like MCP-1 and IFN-γ-inducible peptide, CXCL10, whereas the
“opposition” is through peripheral immune activation (Yadav et al., 2009). Upon entry in the
brain, HIV-1-infected blood-borne macrophages secrete proinflammatory cytokines like
tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and viral proteins which affect
neuronal function (Brabers and Nottet, 2006). Within the brain, astrocytes serve as principal
regulators for neural homeostasis. They bring out a neurotoxic secretory response in macro‐
phages, resulting to upregulation of certain acids and metabolites, chemokines, and cytokine
secretions. They can also alter macrophage phenotype, which may help in neuroprotection.
But on the contrary astrocytes can also influence autocrine and paracrine inflammatory
cascades, which may lead to immune activation, increased viral infection, and allowance of
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cellular entry via BBB (Kraft-Terry et al., 2010). Also CD16+ monocytes are linked to infection
of the brain as they can be easily infected by the virus, they carry virus into the brain and help
in viral dissemination and serve as viral reservoirs as they are apoptosis resistant. HIV proteins
like nef require adaptive selection in brain for efficient replication in macrophages or when it
is exposed to brain specific immune selection (Olivieri et al., 2010). Neuropsychiatric disorders
associated with HIV infection result in substantial morbidity and fatality. HIV injures the CNS
and PNS, leading to neuropsychiatric disorders, which together constitute for neuroAIDS
(McCombe et al.,2009), which includes neurocognitive disorders like HAD, minor neurocog‐
nitive disorder (HAND), mania, anxiety, depression, seizures, myelopathy and neuropathy,
and also involves display of several symptoms like neurocognitive impairment, mood
disorders, neuropathic pain, epilepsy, addiction, physical disability, loss of memory, mood
swings etc (Fig.3).
Figure 3. Associated disorders and symptoms which are commonly seen in patients suffering from neuroAIDS.
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8. Forms of dementia
One form of dementia is Alzheimer’s disease caused by amyloid pathology, during which
peptides of amyloid-β generate and clump together into plaques which release toxic fragments
of amyloid-β leading to neuropathogenesis. Another form of dementia is caused by vascular
pathology in which blood vessels leak and hence deprives small areas of the brain of blood
and oxygen, which damage brain tissue resulting in cognitive defects. Both forms exist equally,
even though Alzheimer pathology is more common, but it coexists with vascular pathology.
(Abott et al., 2011).
TYPES OF DEMENTIA
Dementia type Symptoms Neuropathological findings
Percentage of
total dementia
cases
Alzheimer's
Weakened memory power,
leading to confusion, disinterest
depression and bad judgement
skills.
Formation of amyloid plaques
and also neurofibrillary tangles. 50–80%
Vascular dementia
Memory is weakened, but not as
intense as in the case of
Alzheimer’s patients.
Causing microstrokes due to
reduced blood flow to brain 20–30%
Frontotemporal
dementia
Personality disorders, mood
swings and difficulty in
understanding different
languages.
Damage limited to frontal and
temporal lobes 5–10%
Dementia with
Lewy bodies
Weakened memory power,
leading to confusion, disinterest
depression and bad judgement
skills, hallucinations and tremors.
Cortical Lewy bodies (of the
protein a-synuclein) inside
neurons.
<5%
Table 1. Displaying the types of dementia and their prevelance. (Source: Abbott A. Dementia: a problem for our age.
Nature. 2011; 475(7355): S2-4)
9. Knowing dementia and its diagnosis
Dementia is considered as loss of memory and other cognitive abilities which reduces the
lifespan of patients. Dementia is often associated with physical, mental and financial burden.
37% of the dementic population in developing countries have vulnerable living environ‐
ment and they require specialised care. Diagnosis of dementia involves investigations for
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decline  in  memory  and  disturbance  in  several  cognitive  abilities  like  coherent  speech,
understanding  spoken  or  written  language,  recognizing  objects,  executing  motor  activi‐
ties, sensory function, thinking abstractly, making sound judgments, planning and carrying
out  complex  tasks.  Dementia  reduces  the  lifespan  of  affected  people.  In  the  developed
countries life span after dementia diagnosis can be expected to be ~7 years, but in low and
middle income countries survival may be shorter. Dementia symptoms and linked issues
can  be  understood  in  three  stages  of  early  stage  (1-2  years)  which  is  often  overlooked
because the onset  of  dementia  is  gradual,  making it  difficult  to  predict  when it  begins,
leading to problems in talking, memory loss. Secondly, the middle stage (2-5 years) which
makes patients life more difficult and restricted, giving them difficulty in day-to-day living
and forgetting  recent  events  and  people’s  names,  etc.  Thirdly,  the  late  stage  (>5  years)
leading  to  total  dependence  and  inactivity,  serious  memory  disturbances  difficulty  in
physical works like walking, eating, incapability of communicating, not recognizing familiar
objects, displaying inappropriate behavior in public etc.
HIV associated dementia, referred as the syndrome of cognitive and motor dysfunction
resulting in progressive neurodegeneration observed after infection with human HIV-1, also
known as HIV encephalopathy (HIV-E) and AIDS dementia complex (ADC) (Kaul et al.,
2001). In the last stage of HIV, HAD a severe neurological complication affects 15–20% of the
patients (Van de Bovenkamp et al., 2002). The relationship between spreading of HIV in brain
tissue and pathology has not been thoroughly assessed in HAART era (Lamers et al., 2010).
Inspite of preventing former end stage complications of AIDS by HAART however, with
increased survival times, the prevalence of minor HIV-1 associated cognitive impairment
appears to be rising among AIDS patients. Further, HIV-1 associated dementia (HAD) is still
prevalent in treated patients as well as attenuated forms of HAD and CNS opportunistic
disorders (Ghafouri et al., 2006). Infected macrophages with HIV have an ability to cross BBB
infect inhabitant brain macrophages initiating the development of HAD. Cytokines are
released from infected resident brain macrophages which further attract more macrophages
to sites of infection and a series of self-inflammatory process emerges (Williams et al., 2002).
Studies have suggested that the process of entering in the CNS causing HAD mostly depends
on the HIV variants as some HIV variants have capability of entering in the CNS and develops
HAD but in contrast other variants don’t have capability to develop HAD even after entering
in the CNS (Fischer-Smith et al., 2008; Fischer-Smith et al., 2005).
10. Underlying mechanisms and issues
Some studies suggest that neurological involvement of infected patients occurs at differ‐
ent frequencies, depending on the HIV subtype involved in the infection (Liner 2nd et al.,
2007). HIV-1 Subtype D has more prominent chance for developing dementia (89%) than
subtype A (24%) in the patients localized in a region of Uganda, Africa suggesting genetic
determinants  exist  within  HIV that  influence  the  ability  of  the  virus  to  replicate  in  the
central nervous system. HIV-1 proteins have been shown to be released from HIV infected
cell  and/  or  they  have  found  to  be  present  in  the  extracellular  milieu  in  the  HIV-1-
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infected brain.  In vitro,  neurotoxic and/or neuromodulatory effects have been shown by
HIV proteins: nef, env, tat, rev, vpr and vpu that might play a role in the development of
HIV-1-associated dementia in vivo (Sactor et al., 2009).
11. Fight against dementia
Dementia is engulfing bigger proportion of HIV patients and is expected to worsen more. It is
expected that a significant proportion of dementia is driven by amyloid-β. But so far none of
the amyloid-based strategies has been successful, but still drug developers are strategising on
the concept which can combat against it. More reliable biomarkers are being developed
potentially making it possible to carry out trials on patients before symptoms. Some scientists
are also wondering to target vascular pathology as well, which is equally responsible for
causing dementia. So cholesterol level lowering drugs and blood pressure reducing drugs are
also given long term to patients, who are at higher risk of heart attack which may also help
protect from dementias as well (Abott et al., 2011). There are several extracellular and intra‐
cellular signalling pathways, which when activated lead to macrophage or microglial activa‐
tion, and induction in neurons and astrocytes. These pathways may act as a potential
therapeutic importance as drug targets against neuropathogenesis. NeuroAIDS is challenge
to patients, their families, society and our country, thus development of preclinical models
appropriate for new compounds testing with neurotrophic and neuroprotective potential is
necessary (Crews et al., 2008; Williams et al., 2008).
12. Therapeutic developments
The biggest issue which comes in front of drug developers is the incapability of the drugs to
cross the BBB, which leads to low bioavailability of the drugs into the CNS. HIV-1 protease
inhibitors are totally incapable in entering the CNS, while other HIV-1 therapies such as
zidovudine (AZT) are reported to have efficient BBB penetration. Recently, a broad range of
nanomedicines are being developed to improve drug delivery across BBB, development of
nanoparticulate– antiretroviral therapy (nanoART), against CNS disorders as the structure of
the BBB, efflux pumps and the expression of metabolic enzymes make it difficult for the regular
drug to reach brain. Nanoformulations can evade the BBB and can boost CNS-directed drug
delivery (Fig. 4) (Saxena et al., 2012; Nowacek et al., 2010; Nowacek et al., 2009). Efforts are been
done in finding long-lasting injectable antiretrovirals to avoid the challenges of therapy
adherence (Baert et al., 2009). To specifically target the CNS, NPs are synthesized with various
combinations of ART therapies to be taken up by monocytes and carried into the CNS for
release at sites of HIV-1 infection, for example Indinavir nanoART and p24 loaded and coated
NP, which are providing new avenues for treating or even preventing the spread of HIV-1 in
the brain. Adjunctive therapeutics ART is engaged in making combinatory drugs against virus
mutation. Efforts are being made to improve penetrability of ART across the BBB, but impor‐
tance of considering drug toxicity and elicited cellular response for various ART regiments is
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always a necessity. Adjunctive therapy like platelet-activating factor (PAF) antagonist,
PMS-601, are demonstrated to reduce HAND symptoms and even combination of ART and
PAF antagonists, are also studied to have role in reducing neurodegeneration. All of these are
also being developed as therapies for neurodegenerative disorders which may prove to be a
boon in the combat against NeuroAIDS. Need of the hour is to device an exact combination of
CNS-penetrating nanoART and adjunctive therapies, which might be able to help us against
neurocognitive symptoms (Kraft-Terry et al., 2010).
Figure 4. Comparative display of nanocarrier mediated method of drug delivery (A) versus the classical method of drug de‐
livery across the Blood Brain Barrier (BBB), which is less efficient than the former in the process of drug delivery.
13. Future implications and need of the hour
Since dementia is quite prevalent in HIV patients, in developed countries and has also been
reported to extend its grip towards developing countries as well due to increase in patient
survival rates and life expectancy due to HAART treatment and increased living standards.
Low prevalence of HAD in underdeveloped and developing countries have been attributed
to under diagnosis, short life expectancy and short survival following HIV infection associated
with opportunistic infections and also low prevalence of HIV related neuroinfections and
pathology is not available due to inadequate medical facilities, social stigma and ignorance
that lead to under diagnosis (Vivithanaporn et al., 2010). So a need of collaboratory studies is
there which can be used, for learning the cause, prevalence and diagnosis of neuropathogen‐
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esis. A synchronised effort is needed by researchers, drug makers, physicians, policy makers,
government bodies nationally as well as globally. A proper and deep understanding about the
entry of the virus into the CNS and the various mechanisms it employs to undertake the host
machinery would be of great help in understanding the issue and combating against the virus.
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